Natco Pharma Ltd.

₹802.6

Natco Pharma Ltd.

₹802.6

₹802.6

-33.95 (-4.06%) - 4 Apr 2025 09:58 AM

About Company

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company engaged in developing, manufacturing and marketing of finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs). The company manufactures API products which are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets. In the API segment, company has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides. It is also engaged in contract manufacturing business, whereby it undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products. It has diversified into the business of crop health sciences to leverage is skills in organic chemistry.

Market Cap. ₹14,983 Cr.
52 Week - High/Low ₹1,639/757
P/E Ratio 8.46
P/B Ratio 2.68
Enterprise Value ₹14,188 Cr.
ROE % 25.38
RSI Value 45.42
EMA 50 943.55
EMA 200 1142.17
Net Profit 1,307 Cr.
Net Profit 3year growth 322.16 Cr.
Net Profit 3 year (back) 310 Cr.
Debt to Equity 0.06 %
EPS Growth TTM 47.22 %
Current Ratio 3.85 %
100 Day SMA 1,170 Rs.
200 Day SMA 1,275 Rs.
21 Day SMA 811 Rs.
50 Day SMA 967 Rs.
Book Value 312 Rs.
EV/EBITDA Ratio 6
QoQ EPS Growth -81 %
QoQ Operating Profit Growth -96 %
QoQ Sales Growth -68 %
Sales Latest Quarter 408 Cr.
YoY Sales Growth -35 %
Market Cap. ₹14,983 Cr.
52 Week - High/Low ₹1,639/757
P/E Ratio 8.03
P/B Ratio 2.56
Enterprise Value ₹14,092 Cr.
ROE % 25.88
RSI Value 45.42
EMA 50 943.55
EMA 200 1142.17
Net Profit 1,388 Cr.
Net Profit 3year growth 10.31 Cr.
Net Profit 3 year (back) 441 Cr.
Debt to Equity 0.06 %
EPS Growth TTM 46.96 %
Current Ratio 4.14 %
100 Day SMA 1,170 Rs.
200 Day SMA 1,275 Rs.
21 Day SMA 811 Rs.
50 Day SMA 967 Rs.
Book Value 327 Rs.
EV/EBITDA Ratio 6
QoQ EPS Growth -80 %
QoQ Operating Profit Growth -95 %
QoQ Sales Growth -65 %
Sales Latest Quarter 475 Cr.
YoY Sales Growth -37 %

Growth

Valuation

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.